Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Neurology

Volumn 71, Issue 10, 2008, Pages 766-773

  Goodin, D S ^a   Cohen, B A ^b   O'Connor, P ^c   Kappos, L ^d   Stevens, J C ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e Lutheran Medical Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO; MONOCLONAL ANTIBODY;

ANAPHYLAXIS; ATYPICAL MYCOBACTERIOSIS; BIOMEDICAL TECHNOLOGY ASSESSMENT; BURKHOLDERIA CEPACIA INFECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DISABILITY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LUNG ASPERGILLOSIS; MONOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS ENCEPHALITIS; VIRUS MENINGITIS;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 54049087015     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000320512.21919.d2     Document Type: Article

References (40)

1. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58:169-178.
2. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120: 393-399.
3. Peterson JW, Bo L, Mork S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
4. Bar-Or A, Oliviera EML, Anderson DE, Hafler DA. Molecular pathogenesis of multiple sclerosis. J Neuroimmunol 1999;100:252-259.
5. Conlon P, Oksenberg JR, Zhang J. The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system. Neurobiol Dis 1999;6:149-166.
6. International Federation of Multiple Sclerosis Societies. Symposium on a minimal record of disability in multiple sclerosis. Acta Neurol Scand 1984;70 (suppl 101):176-181.
7. Davis LS, Oppenheimer-Marks N, Bednarczyk JL, McIntyre BW, Lipsky PE. Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J Immunol 1990; 145:785-793.
8. Chan PY, Aruffo A. VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J Biol Chem 1993;268:24655-24664.
9. O'Regan AW, Chupp GL, Lowry JA, Goetschkes M, Mulligan N, Berman JS. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol 1999;162: 1024-1031.
10. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001;294: 1731-1735.
11. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992;356:63-66.
12. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747.
13. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006;59:748-754.
14. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS: The UK Antegren Study Group. Neurology 1999;53: 466-472.
15. Miller DH, Khan OA, Sheremata WA, et al., International Natalizumab Multiple Sclerosis Trial Group . A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
16. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al., Natalizumab Multiple Sclerosis Trial Group. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004;62:2038-2043.
17. O'Connor P, Miller D, Riester K, et al., International Natalizumab Trial Group. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler 2005;11:568-572.
18. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374.
19. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelle-tier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353: 375-381.
20. Polman CH, O'Connor PW, Havrdova E, et al. ., AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
21. Rudick RA, Stuart WH, Calabresi PA, et al., SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923.
22. Calabresi PA, Giovannoni G, O'Connor PW, et al. The incidence and significance of antibodies to natalizumab over 2 years of treatment in patients with multiple sclerosis. Neurology 2006;66 (suppl 2):A312.
23. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-933.
24. Goodman AD, Rossman HS, Bar-Or A, et al. GLANCE: a double-blind, randomized, placebo-controlled parallel-group safety study of natalizumab in combination with glatiramer acetate in subjects with relapsing-remitting multiple sclerosis. Neurology 2005;64 (suppl 1):A277-278.
25. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993;43:655-661.
26. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in remitting and relapsing multiple sclerosis: II: MRI analysis results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 1993;43:662-667.
27. The IFNB Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group. Interferon Beta-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
28. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol 1996;39:285-294.
29. Simon JH, Jacobs LD, Campion M, et al., and the Multiple Sclerosis Collaborative Research Group (MSCRG). Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 1996;43: 79-87.
30. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
31. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebocontrolled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.
32. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/ remitting multiple sclerosis. Lancet 1998;352:1498-1504.
33. Li DK, Paty DW, UBC MS/MRI Analysis Research Group, PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis: prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999;46:197-206.
34. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:2018-2025.
35. Krapf H, Morrissey SP, Zenker O, et al., and the MIMS Study Group. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005;65: 690-695.
36. Jacobs LD, Beck RW, Simon JH, et al.and the CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. . N Engl J Med 2000;343:898-904.
37. Comi G, Filippi M, Barkhof F. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582.
38. Kappos L, Polman CH, Freedman MS, et al., and the BENEFIT Study Group. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249.
39. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368.
40. Center for Drug Evaluation and Research (CDER). Peripheral and Central Nervous System Drugs Advisory Committee; FDA Advisory Hearing, March 7-8, 2006. Available at: www.fda.gov/ohrms/dockets/ac/06/slides/ 2006-4208S1-Slide-Index. htm. Accessed February 2007.